FINNENCE ▪ THE WIRE FILE
THE WIRE · № 68904
News■ Unclear/unknown
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 11:00 UTC
LAST UPDATE2026-10-07 11:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Patent issuances extend exclusivity but do not change near-term cash flows.
Armata extends IP runway for candidates
CATALYST TO WATCH
Clinical trial progress for AP-SA02
MAIN RISK
Patents do not guarantee approval
FULL DISPATCH
Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041 LOS ANGELES, Oct. 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 20262026-10-07 11:00 UTC
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 20262026-10-07 11:00 UTC
→CORRELATIONshares Healthcare
Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri2026-10-07 11:00 UTC
Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri2026-10-07 11:00 UTC
→CORRELATIONshares Healthcare
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development2026-10-07 11:03 UTC
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development2026-10-07 11:03 UTC
→CORRELATIONshares Healthcare
Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)2026-10-07 11:08 UTC
Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)2026-10-07 11:08 UTC
→CORRELATIONshares Healthcare
Health Transformation Alliance and State Financial Officers Foundation Announce Corporate Health Plan Fiduciary Scorecard2026-10-07 11:17 UTC
Health Transformation Alliance and State Financial Officers Foundation Announce Corporate Health Plan Fiduciary Scorecard2026-10-07 11:17 UTC
→CORRELATIONshares Healthcare
Infinitus Launches FieldForce to Extend the Reach of Pharmaceutical Sales and Reimbursement Teams2026-10-07 11:30 UTC
Infinitus Launches FieldForce to Extend the Reach of Pharmaceutical Sales and Reimbursement Teams2026-10-07 11:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.